Click on headlines below to download research

Clarity on pathway to US approval
Oasmia Pharmaceutical | 17/12/2020

Oasmia’s H1 FY21 results highlight recent developments made to realign the business. In December, global partner Elevar Therapeutics announced it…

Executive interview
Oasmia Pharmaceutical – executive interview | 17/12/2020

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs that are delivered intravenously through…

An appealing metamorphosis
Oasmia Pharmaceutical | 09/09/2020

Oasmia is a specialty pharma company focused on developing improved formulations of well-established cancer drugs through its proprietary XR-17 platform…